AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14574035 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (calcium channel blocker)
Number of subjects: 0
Study 14574035 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (angiotensin receptor blocker)
Number of subjects: 0
Study 14574035 — intervention group
Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 0
Study 14574035 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control strategy
Number of subjects: 0
Study 14574035 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation
Number of subjects: 0
Study 14574035 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril after myocardial infarction
Number of subjects: 0
Study 14574035 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic pacing
Number of subjects: 0
Study 11080465 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseload midwifery care
Number of subjects: 1505
Study 11080465 — intervention group
Group type: COMPARATOR
Intervention: Traditional 'shared care'
Number of subjects: 1505
Study 8840920 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatable foods
Number of subjects: 0
Study 8840920 — intervention group
Group type: COMPARATOR
Intervention: Unpalatable foods
Number of subjects: 0
Study 8840920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restraint (measured by the Three Factor Eating Questionnaire)
Number of subjects: 0
Study 1497127 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (Fl) with Fentanyl (Fe)
Number of subjects: 15
Study 1497127 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl) with Fentanyl (Fe)
Number of subjects: 15
Study 6653134 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg)
Number of subjects: 33
Study 6653134 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 33
Study 31718254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg/day
Number of subjects: 76
Study 31718254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg/day
Number of subjects: 76
Study 31718254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 70 mg/day
Number of subjects: 76
Study 31718254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 31718254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/day
Number of subjects: 76
Study 31366435 — intervention group
Group type: COMPARATOR
Intervention: Written vaccination appeal sent by physicians to patients
Number of subjects: 0
Study 31366435 — intervention group
Group type: COMPARATOR
Intervention: Written vaccination appeal sent to nephrologists
Number of subjects: 0
Study 31366435 — intervention group
Group type: COMPARATOR
Intervention: Written vaccination appeal sent by health-insurance fund to patients
Number of subjects: 0
Study 29130647 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES)
Number of subjects: 21
Study 29130647 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 21
Study 29130647 — intervention group
Group type: COMPARATOR
Intervention: Sham control (inactive laser acupuncture)
Number of subjects: 21
Study 29130647 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (TES, electro-acupuncture, sham control)
Number of subjects: 21
Study 26794472 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-spectrum antibiotics
Number of subjects: 769
Study 24855214 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D echocardiography (3DE) LV volumes
Number of subjects: 60
Study 24855214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D echocardiography (2DE) LV volumes
Number of subjects: 60
Study 24855214 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D RF ≥40%
Number of subjects: 60
Study 24855214 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D RF ≤30%
Number of subjects: 60
Study 24855214 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D RF between 30 and 40%
Number of subjects: 60
Study 24855214 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D RF
Number of subjects: 60
Study 24855214 — intervention group
Group type: EXPERIMENTAL
Intervention: MR grading by two cardiologists
Number of subjects: 60
Study 22708519 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural Ecosystems Therapy (SET)
Number of subjects: 126
Study 22708519 — intervention group
Group type: COMPARATOR
Intervention: Psycho-educational health group (HG)
Number of subjects: 126
Study 22708519 — intervention group
Group type: EXPERIMENTAL
Intervention: Family drug abstinence
Number of subjects: 126
Study 20179658 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol HFA 180 microg
Number of subjects: 87
Study 20179658 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol HFA 360 microg
Number of subjects: 87
Study 17343553 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 340
Study 17343553 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulants
Number of subjects: 340
Study 17343553 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant to Atomoxetine switch
Number of subjects: 340
Study 17343553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 16266860 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 40
Study 16266860 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (sIMV)
Number of subjects: 40
Study 17008634 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SBP <140 mm Hg
Number of subjects: 7697
Study 17008634 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 3 consecutive measurements of SBP <120 mm Hg
Number of subjects: 7697
Study 12580231 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated noninvasive blood pressure (ANIBP) measurements in the arm
Number of subjects: 73
Study 12580231 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated noninvasive blood pressure (ANIBP) measurements in the calf
Number of subjects: 73
Study 12580231 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ANIBP measurements between arm and calf
Number of subjects: 73
Study 8646094 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose bupivacaine
Number of subjects: 599
Study 8646094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose bupivacaine with opioid
Number of subjects: 599
Study 8646094 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 599
Study 8646094 — intervention group
Group type: COMPARATOR
Intervention: No epidural analgesia
Number of subjects: 599
Study 1538159 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160 vaccine (40 micrograms, three doses on days 0, 30, and 180)
Number of subjects: 17
Study 1538159 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (control)
Number of subjects: 17
Study 1538159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from HIV-1 antibody-negative volunteers (before vaccination)
Number of subjects: 17
Study 1538159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from vaccinated volunteers (after vaccination)
Number of subjects: 17
Study 6337801 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol (SR-OX) once daily
Number of subjects: 178
Study 6337801 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol (OX) twice daily
Number of subjects: 178
Study 31118469 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical colour stimuli reflecting human perceptual constraints on colours
Number of subjects: 0
Study 31118469 — intervention group
Group type: COMPARATOR
Intervention: Randomised stimuli that distort perceptual constraints
Number of subjects: 0
Study 29095706 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of exercise and falls prevention education
Number of subjects: 24
Study 29095706 — intervention group
Group type: COMPARATOR
Intervention: Falls prevention education only
Number of subjects: 24
Study 26701163 — intervention group
Group type: EXPERIMENTAL
Intervention: Video/computer‐based interactive exercises for 1 hour on weekdays, mainly involving stepping and weight‐shifting exercises.
Number of subjects: 58
Study 26701163 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 58
Study 26701163 — intervention group
Group type: EXPERIMENTAL
Intervention: Video/computer‐based interactive exercises.
Number of subjects: 58
Study 24700145 — intervention group
Group type: EXPERIMENTAL
Intervention: High-variability condition (24 unique verbs)
Number of subjects: 18
Study 24700145 — intervention group
Group type: COMPARATOR
Intervention: Low-variability condition (12 unique verbs)
Number of subjects: 18
Study 22844025 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic rehabilitation
Number of subjects: 0
Study 22844025 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 20491770 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ALA
Number of subjects: 180
Study 20491770 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% ALA
Number of subjects: 180
Study 20491770 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% ALA
Number of subjects: 180
Study 20491770 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% ALA
Number of subjects: 180
Study 20491770 — intervention group
Group type: COMPARATOR
Intervention: Placebo agent (control)
Number of subjects: 180
Study 18614736 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg Zn + 60 mg Fe + 250 microg folic acid)
Number of subjects: 1295
Study 18614736 — intervention group
Group type: COMPARATOR
Intervention: Control (60 mg Fe + 250 microg folic acid)
Number of subjects: 1295
Study 18614736 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 1295
Study 18614736 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1295
Study 16094739 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate thoracic radiotherapy (TRT)
Number of subjects: 407
Study 11956673 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (1 liter daily for 3 days)
Number of subjects: 24
Study 11956673 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 24
Study 11956673 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 24
Study 10066994 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory backward masking in schizophrenic participants
Number of subjects: 30
Study 10066994 — intervention group
Group type: COMPARATOR
Intervention: Auditory backward masking in controls
Number of subjects: 30
Study 10066994 — intervention group
Group type: EXPERIMENTAL
Intervention: No-mask performance in schizophrenic participants
Number of subjects: 30
Study 10066994 — intervention group
Group type: COMPARATOR
Intervention: No-mask performance in controls
Number of subjects: 30
Study 7726447 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + 250 mg acipimox (a nicotinic acid compound) two to three times/day
Number of subjects: 85
Study 7726447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypolipidemic diet
Number of subjects: 85
Study 7726447 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized group (reference population)
Number of subjects: 85
Study 31220365 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and treatment for fracture risk
Number of subjects: 11032
Study 29616481 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga breathing (YB)
Number of subjects: 32
Study 29616481 — intervention group
Group type: COMPARATOR
Intervention: Standard breathing
Number of subjects: 32
Study 27315267 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tRNS
Number of subjects: 0
Study 27315267 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 25377966 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) used for the repair of ear drum perforation
Number of subjects: 32
Study 25377966 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 32
Study 22504100 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb technique on the floor
Number of subjects: 20
Study 22504100 — intervention group
Group type: COMPARATOR
Intervention: Two-finger technique on the floor
Number of subjects: 20
Study 22504100 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb technique on the table
Number of subjects: 20
Study 22504100 — intervention group
Group type: COMPARATOR
Intervention: Two-finger technique on the table
Number of subjects: 20
Study 22504100 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb technique on the radiant warmer
Number of subjects: 20
Study 22504100 — intervention group
Group type: COMPARATOR
Intervention: Two-finger technique on the radiant warmer
Number of subjects: 20
Study 19652068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 100 mg/m²/day intravenously on days 1 to 2, repeated every 4 weeks for a maximum of six cycles.
Number of subjects: 319
Study 19652068 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil 0.8 mg/kg orally on days 1 and 15, repeated every 4 weeks for a maximum of six cycles.
Number of subjects: 319
Study 19652068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 319
Study 19652068 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 319
Study 17118682 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 118
Study 15036825 — intervention group
Group type: EXPERIMENTAL
Intervention: FBG monitoring group with titration target 4.4-6.1 mmol/l
Number of subjects: 385
Study 15036825 — intervention group
Group type: COMPARATOR
Intervention: PPBG monitoring group with titration target 4.4-8.0 mmol/l
Number of subjects: 385
Study 11197251 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (5 mg/day)
Number of subjects: 20
Study 11197251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10920943 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucomax (rhGM-CSF)
Number of subjects: 57
Study 10920943 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy alone
Number of subjects: 57
Study 8305998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 17703
Study 8305998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 17703
Study 8305998 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patch
Number of subjects: 17703
Study 8305998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal spray
Number of subjects: 17703
Study 8305998 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nicotine
Number of subjects: 17703
Study 8305998 — intervention group
Group type: COMPARATOR
Intervention: Control interventions
Number of subjects: 17703
Study 2543492 — intervention group
Group type: EXPERIMENTAL
Intervention: Central parenteral nutrition (CPN)
Number of subjects: 24
Study 2543492 — intervention group
Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN)
Number of subjects: 24
Study 2543492 — intervention group
Group type: COMPARATOR
Intervention: Both CPN and PPN
Number of subjects: 24
Study 1101843 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine, 20 mg/day
Number of subjects: 96
Study 1101843 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline-perphenazine, 20 mg/day
Number of subjects: 96
Study 1101843 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride, 125 mg/day
Number of subjects: 96
Study 1101843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 31209560 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A supplementation (10,000 IU/dose; n=98)
Number of subjects: 196
Study 31209560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=98)
Number of subjects: 196
Study 28506228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulian ointment
Number of subjects: 294
Study 28506228 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 294
Study 26173573 — intervention group
Group type: EXPERIMENTAL
Intervention: Video modeling (VM)
Number of subjects: 0
Study 26173573 — intervention group
Group type: COMPARATOR
Intervention: Text-based instruction
Number of subjects: 0
Study 26173573 — intervention group
Group type: COMPARATOR
Intervention: No instruction
Number of subjects: 0
Study 23468338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp incremental test
Number of subjects: 13
Study 23468338 — intervention group
Group type: COMPARATOR
Intervention: Step incremental test
Number of subjects: 13
Study 21518005 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly derived dental pulp tissues (Group A)
Number of subjects: 50
Study 21518005 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen (liq N(2))-stored dental pulp tissues (Group B)
Number of subjects: 50
Study 21518005 — intervention group
Group type: COMPARATOR
Intervention: Liquid nitrogen (liq N(2))-stored intact teeth (Group C)
Number of subjects: 50
Study 18505369 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide for 24 months
Number of subjects: 503
Study 16566731 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ALA-PDT plus 3% azone
Number of subjects: 36
Study 16566731 — intervention group
Group type: COMPARATOR
Intervention: 5-ALA-PDT alone
Number of subjects: 36
Study 12656905 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 156
Study 12656905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnoxicam (30 mg suppository every 4 days for 12 months)
Number of subjects: 156
Study 12656905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycerine suppository every 4 days for 12 months)
Number of subjects: 156
Study 11078249 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm split-tip ablation catheter
Number of subjects: 30
Study 11078249 — intervention group
Group type: COMPARATOR
Intervention: 4-mm tip ablation catheter
Number of subjects: 30
Study 8625641 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of daily itemized patient charges during the intervention period
Number of subjects: 598
Study 8625641 — intervention group
Group type: COMPARATOR
Intervention: Control group (no availability of daily itemized patient charges)
Number of subjects: 598
Study 1290473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal insemination
Number of subjects: 26
Study 1290473 — intervention group
Group type: COMPARATOR
Intervention: Timed intercourse (control)
Number of subjects: 26
Study 6377610 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A+B matching
Number of subjects: 0
Study 6377610 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DR matching
Number of subjects: 0
Study 6377610 — intervention group
Group type: EXPERIMENTAL
Intervention: Other factors (blood transfusion, preformed antibodies, graft number, recipient sex)
Number of subjects: 0
Study 6377610 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-B+DR matching
Number of subjects: 0
Study 28858971 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based training program for 12 weeks
Number of subjects: 80
Study 28858971 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study 27103767 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthKick intervention
Number of subjects: 998
Study 25072976 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pressure dressing (elastic bandage or general wrapping) applied 7 to 10 days after DC
Number of subjects: 169
Study 25072976 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (general wrapping)
Number of subjects: 169
Study 25072976 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pressure dressing
Number of subjects: 169
Study 25072976 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 169
Study 22349069 — intervention group
Group type: EXPERIMENTAL
Intervention: HTS 6%
Number of subjects: 40
Study 22349069 — intervention group
Group type: COMPARATOR
Intervention: IS 0.9%
Number of subjects: 40
Study 20622362 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (Cisplatinum 40 mg/m2 and 5 Fluorouracil 500 mg/m2 continuous infusions with radiotherapy on D2-D5 in first and last 5 sessions of radiation therapy)
Number of subjects: 102
Study 20622362 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Control group)
Number of subjects: 102
Study 20622362 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Concurrent chemoradiation and Control)
Number of subjects: 102
Study 18757458 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 54
Study 18757458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 14999109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (0.5 to 1.0 g per square meter of body‐surface area) plus corticosteroids
Number of subjects: 59
Study 14999109 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (500 to 3000 mg per day)
Number of subjects: 59
Study 14999109 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (1 to 3 mg per kilogram of body weight per day)
Number of subjects: 59
Study 14999109 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (long-term therapy)
Number of subjects: 59
Study 12372041 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose tacrolimus (trough 12-17 ng/mL)
Number of subjects: 28
Study 12372041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose tacrolimus (trough 5-10 ng/mL)
Number of subjects: 28
Study 9522106 — intervention group
Group type: EXPERIMENTAL
Intervention: System I (investigational testosterone transdermal system)
Number of subjects: 33
Study 9522106 — intervention group
Group type: COMPARATOR
Intervention: System II (marketed testosterone transdermal system)
Number of subjects: 33
Study 9522106 — intervention group
Group type: COMPARATOR
Intervention: System I vs System II
Number of subjects: 33
Study 9522106 — intervention group
Group type: EXPERIMENTAL
Intervention: Older men
Number of subjects: 33
Study 7652966 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 1881